SK609 (ES609) is a Dopamine D3 receptor (D3R) selective agonist with a bias towards the G-protein-dependent pathway rather than recruiting β-arrestin-2 and an EC50 value of 113.9 nM for activation of ERK1/2 phosphorylation. SK609 has been shown to reverse akinesia and reduce L-dopa-induced dyskinesia in a hemiparkinsonian r at model of Parkinsonμs desease. It does not induce desensitization of D3R.
